Genmab A/S (GMAB)

Market Cap	14.16B
Revenue (ttm)	2.99B
Net Income (ttm)	1.09B
Shares Out	63.54M
EPS (ttm)	16.85
PE Ratio	13.00
Forward PE	14.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	383,929
Open	22.07
Previous Close	22.44
Day's Range	22.32 - 22.36
52-Week Range	18.64 - 31.88
Beta	0.86
Analysts	Buy
Price Target	40.71 (+83.79%)
Earnings Date	Feb 12, 2025

About GMAB

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 2,678
• Stock Exchange: NASDAQ
• Ticker Symbol: GMAB
• Website: https://www.genmab.com

Financial Performance

In 2024, Genmab's revenue was 21.53 billion, an increase of 30.67% compared to the previous year's 16.47 billion. Earnings were 7.84 billion, an increase of 80.24%.

Financial numbers in DKK

Analyst Forecast

According to 9 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $40.71, which is an increase of 83.79% from the latest price.

Price Target

$40.71

(83.79% upside)

Analyst Consensus: Buy